Table 5 Multivariate analysis for biopsies taken after the last line of therapy (ACT).

From: Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

Ā 

DCB rates (%)

Multivariate OR (95% CI)

p value

Tumour PD-L1 expression

Ā Ā 

0.047

Ā <1% (n = 47)

23

1.0

Ā 

Ā 1–50% (n = 9)

22

0.78 (0.13–4.8)

Ā 

 ≄50% (n = 13)

69

6.5 (1.4–30.7)

Ā 

Combined tumour and stromal infiltration of CD8+ IC

Ā Ā 

0.012

Ā Low infiltration of tumour and stromal CD8+ IC (n = 31)

19

1.0

Ā 

Ā High infiltration of tumour or stromal CD8+ IC (n = 11)

9

0.29 (0.026–3.1)

Ā 

Ā High infiltration of tumour and stromal CD8+ IC (n = 28)

54

4.5 (1.3–15.9)

Ā 
  1. Statistically significant p < 0.05 values are in bold